Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 328 participants.

Also called NCT05982470

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 328 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05982470
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05982470. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-18 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI
Acronym
MIRACLE
Condition
Cerebral Small Vessel Diseases
Condition
Postmenopausal Symptoms
Condition
Mild Cognitive Impairment
Condition
White Matter Hyperintensity
Intervention (Drug)
Estradiol Gel
Intervention (Drug)
Estradiol Placebo Gel
Intervention (Drug)
Progesterone Soft Capsule
Intervention (Drug)
Progesterone Placebo Soft Capsule
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05982470
Content hash
42eacdd34aa3b527406c266286256d35f768f23e832f8fad79ce725e64872c1b